23Andme Holding Co. (NQ: ME )
0.5443 -0.0257 (-4.51%) Streaming Delayed Price Updated: 4:00 PM EST, Mar 1, 2024 Add to My Watchlist
Press Releases about 23Andme Holding Co.
23andMe to Report FY2024 Third Quarter Financial Results
January 24, 2024
23andMe Launches Total Health™, its Comprehensive, Prevention-Based Health Membership
November 07, 2023
The Company’s first-of-its-kind health membership combines exome sequencing, blood testing and direct access to clinicians trained in genetics for ongoing disease prevention and early detection
23andMe Launches Health Action Plan to Provide Personalized Recommendations Based on Genetic and Other Health Data
October 31, 2023
23andMe+ members will receive customized action plans, from recommended lifestyle changes to clinician-ordered lab tests through 23andMe
23andMe Announces Collaboration Extension with a New Data Licensing Agreement with GSK
October 30, 2023
Following their five year discovery collaboration, 23andMe and GSK have extended their collaboration by entering into a new non-exclusive data licensing agreement, enabling GSK to utilize the 23andMe...
23andMe to Report FY2024 Second Quarter Financial Results
October 25, 2023
23andMe Announces Poster Presentations on 23ME-00610, an Investigational Antibody Targeting CD200R1, at The Society for Immunotherapy of Cancer’s (SITC) 2023 Annual Meeting
September 27, 2023
23andMe to present data on efficacy and safety and dose selection for the ongoing 23ME-00610 Phase 1/2a clinical trial in patients with advanced solid malignancies
23andMe Reports FY2024 First Quarter Financial Results
August 08, 2023
23andMe to Report FY2024 First Quarter Financial Results
July 25, 2023
23andMe Releases New Report Revealing Genetic Likelihood of Experiencing Panic Attacks
June 21, 2023
With millions of Americans experiencing mental health symptoms, 23andMe+ members now have exclusive access to four mental health reports to help determine their genetic likelihood of having one of...
23andMe Announces Presentation of Phase 1 Clinical Data for 23ME-00610, an Investigational Antibody Targeting CD200R1, at the American Association for Cancer Research (AACR) Annual Meeting 2023
March 14, 2023
Data from the Phase 1 portion of the 23ME-00610 Phase 1/2a study, including safety, pharmacokinetics, and the recommended Phase 2a dose to be presented
23andMe Announces First Patient Dosed for the Phase 2a Portion of its Phase 1/2a Study of 23ME-00610, an Investigational Antibody Targeting CD200R1 in Patients with Advanced Solid Malignancies
February 28, 2023
The expansion portion of the study will evaluate the anti-cancer activity of 23ME-00610 in specific tumor indications, and will further characterize the safety, tolerability, pharmacokinetic and...